VideoHIVRSVINTEREST 2024Tenofovir and Doravirine Are Potential Reverse-Transcriptase Analogs for Combination With the New Reverse-Transcriptase Translocation Inhibitor (Islatravir) Among (...) - Alex Durand Nka, CameroonView Video
VideoHIVRSVINTEREST 2024Eligibility for Long-Acting Cabotegravir/Rilpivirine and Archived Drug Resistance Mutations Among People Living with HIV-1 subtype C in Botswana - Dorcas Maruapula, BotswanaView Video
VideoHIVRSVINTEREST 2024Inability-To-Walk-Unaided - A Single WHO Danger Sign Predicts In- Hospital Mortality in People Living With HIV in a Low-Resource Setting - Chikaiko Malunda, MalawiView Video
VideoHIVRSVINTEREST 2024Interrupting the Unending Cycles of Emerging and Re-Emerging Diseases Outbreaks - A Possibility or Pipe Dream! - Ifedayo Adetifa, MBBS, FWACP (Paediatrics), MSc, PhDView Video
VideoHIVRSVINTEREST 2024The Road to 95-95-95: Progress in HIV Prevention and Treatment Scale-up in Sub-Saharan Africa - Berthilde GahongayireView Video
AEAnthony EnimilMDVideoHIVRSVInternational Workshop on Pediatrics & HIV 2024Transition of Youth Living With HIV to Adult Care: Low-Resource Country Experience - Anthony EnimilView Video
AEAnthony EnimilMDVideoHIVRSVInternational Workshop on Pediatrics & HIV 2024Transition of Youth Living With HIV to Adult Care: High-Resource Country Experience - Caroline FosterView Video
VideoHIVRSVInternational Workshop on Pediatrics & HIV 2024Effectiveness and Safety of Tenofovir Alafenamide Fumarate (TAF)-Based Therapy Compared to Tenofovir Disoproxil Fumarate (TDF)- And Abacavir (ABC)-Based Therapy in Children and Adolescents Living With HIV (CALHIV) (...) - Elizabeth ChappellView Video
VideoHIVRSVInternational Workshop on Pediatrics & HIV 2024#19 - Adolescents and Young Adults with HIV Using Long-Acting Injectable Cabotegravir/Rilpivirine as a Standard of Care: Outcomes of the Observational Cohort at 26 months - Tierra WilliamsView Video
